Skip to main content
. 2024 May 8;19(1):2349980. doi: 10.1080/15592294.2024.2349980

Figure 4.

Figure 4.

Disease-free survival (DFS) for patients treated with FU/LV vs IFL based on ZNF331 promoter methylation status. Interaction of ZNF331 promoter methylation status and treatment arm on disease-free survival: (a) unmethylated ZNF331 and (b) methylated ZNF331. There was no observed difference in DFS based on a two-way interaction model between treatment arm and ZNF331 promoter methylation status. (c) Evaluation of ZNF331 promoter methylation status as a predictive marker of DFS.